The global biomarker clinical phase outsourcing services market size was estimated to be USD 7.43 billion in 2023 and is expected to reach at USD 59.07 billion by 2034 with a CAGR of 20.74% during the forecast period 2024-2034. Expanding use of biomarkers in diagnostic applications, surge in the adoption of data-driven & digital technologies in clinical trials encompassing the analysis of biomarkers, rapid advancements in genomics, proteomics, & imaging, increasing shift towards precision medicine, rising advancements in biomarker technology, enhanced patient outcomes, growing research & development (R&D) efforts in the field of diagnostic assays, surge in government funding for research & development, and increasing adoption of biomarkers for early & precise disease detection are some of the key factors boosting the market growth.
Increasing adoption of biomarkers for early & precise disease detection is predicted to boost the market growth during the forecast period. Biomarkers are quantifiable signals that provide insights into the existence, development, or intensity of a condition or illness. Consequently, the use of biomarkers for various chronic diseases has experienced substantial expansion. For instance, in April 2023, Zentalis Pharmaceuticals has included a groundbreaking predictive biomarker, ZN-c3, in its pipeline for patients with advanced solid tumors.
By biomarker type, predictive biomarkers was the highest revenue-grossing segment in the global biomarker clinical phase outsourcing services market in 2023 owing to the growing portfolio of pipeline products of potential biomarkers by multiple pharmaceutical companies, increasing focus on development of predictive biomarkers for various disease indications by biopharmaceutical and pharmaceutical sectors. For instance, in April 2023, AstraZeneca's pipeline features Potdevin, G; an initial evaluation of 89-Zr-Crefmirlimab with CD8-PET/CT as a predictive biomarker to determine the response of patients with solid tumors. Additionally. surrogate endpoints is predicted to grow at fastest CAGR during the forecast period owing to the surge in investment from contract researchers dedicated to developing surrogate endpoints for diagnosing & monitoring various chronic diseases.
By therapeutic area, oncology was the highest revenue-grossing segment in the global biomarker clinical phase outsourcing services market in 2023 owing to the rising utilization of biomarkers in oncology clinical trials and increasing number of cancer trials incorporating biomarker analysis to enhance the efficiency of treatment discovery. Additionally, autoimmune diseases is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of clinical research studies conducted across diseases related to autoimmune conditions and growing research & development activities. For instance, in March 2023, AbbVie Inc. has reported favorable outcomes from a Phase 2 clinical trial of Upadacitinib in patients dealing with moderately to severely active systemic lupus erythematosus, a multifaceted autoimmune disorder.
By end-user, biotechnology companies was the highest revenue-grossing segment in the global biomarker clinical phase outsourcing services market in 2023 owing to the growing number of biopharmaceutical companies that are actively involved in advancing the development of novel biomarkers for the diagnosis & monitoring of various chronic illnesses and increasing collaborations within market players. For instance, in August 2023, The University of South Australia and Quest Diagnostics have revealed a partnership with Envision Sciences to introduce a new biomarker test for prostate cancer. This test is designed to aid in the identification of patients with especially aggressive forms of the disease. Additionally, pharmaceutical companies is predicted to grow at fastest CAGR during the forecast period owing to the rising number of pharmaceutical companies actively investing in the development of novel drugs that necessitate biomarker testing and surge in research & development activities.
North America region is anticipated for the highest revenue share during the forecast period owing to the existence of well-established Contract Research Organizations (CROs) with a specialization in providing biomarker services, increasing demand for outsourcing biomarker services due to the rising research & development investments made by companies in the life sciences & pharmaceutical sectors, growing number of pharmaceutical companies are showing a preference for outsourcing their manufacturing services to Contract Research Organizations (CROs), and rising collaborations within market players. For instance, in March 2023, Fujirebio Holdings Inc., a contract development and manufacturing organization, has joined forces with AriBio Co., Ltd. to collaborate on the development of specific biomarkers for Alzheimer's disease and other neurodegenerative disorders. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in the number of clinical trial activities driven by supportive regulatory reforms & cost-effective clinical research options, the existence of facilities approved by regulatory bodies such as the U.S. FDA & European Medicines Agency in emerging regional economies is expected to attract foreign investments, and increasing partnerships & collaborations within market players. For instance, in July 2023, Eisai Co., Ltd. and Biogen Inc. have disclosed that a comprehensive analysis of the Phase 3 Clarity AD study has revealed that Lecanemab-Irmb (LEQEMBI) treatment led to reductions in amyloid-beta (Aβ) pathology and changes in downstream biomarkers.
Increasing adoption of biomarkers for early & precise disease detection is predicted to boost the market growth during the forecast period. Biomarkers are quantifiable signals that provide insights into the existence, development, or intensity of a condition or illness. Consequently, the use of biomarkers for various chronic diseases has experienced substantial expansion. For instance, in April 2023, Zentalis Pharmaceuticals has included a groundbreaking predictive biomarker, ZN-c3, in its pipeline for patients with advanced solid tumors.
By biomarker type, predictive biomarkers was the highest revenue-grossing segment in the global biomarker clinical phase outsourcing services market in 2023 owing to the growing portfolio of pipeline products of potential biomarkers by multiple pharmaceutical companies, increasing focus on development of predictive biomarkers for various disease indications by biopharmaceutical and pharmaceutical sectors. For instance, in April 2023, AstraZeneca's pipeline features Potdevin, G; an initial evaluation of 89-Zr-Crefmirlimab with CD8-PET/CT as a predictive biomarker to determine the response of patients with solid tumors. Additionally. surrogate endpoints is predicted to grow at fastest CAGR during the forecast period owing to the surge in investment from contract researchers dedicated to developing surrogate endpoints for diagnosing & monitoring various chronic diseases.
By therapeutic area, oncology was the highest revenue-grossing segment in the global biomarker clinical phase outsourcing services market in 2023 owing to the rising utilization of biomarkers in oncology clinical trials and increasing number of cancer trials incorporating biomarker analysis to enhance the efficiency of treatment discovery. Additionally, autoimmune diseases is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of clinical research studies conducted across diseases related to autoimmune conditions and growing research & development activities. For instance, in March 2023, AbbVie Inc. has reported favorable outcomes from a Phase 2 clinical trial of Upadacitinib in patients dealing with moderately to severely active systemic lupus erythematosus, a multifaceted autoimmune disorder.
By end-user, biotechnology companies was the highest revenue-grossing segment in the global biomarker clinical phase outsourcing services market in 2023 owing to the growing number of biopharmaceutical companies that are actively involved in advancing the development of novel biomarkers for the diagnosis & monitoring of various chronic illnesses and increasing collaborations within market players. For instance, in August 2023, The University of South Australia and Quest Diagnostics have revealed a partnership with Envision Sciences to introduce a new biomarker test for prostate cancer. This test is designed to aid in the identification of patients with especially aggressive forms of the disease. Additionally, pharmaceutical companies is predicted to grow at fastest CAGR during the forecast period owing to the rising number of pharmaceutical companies actively investing in the development of novel drugs that necessitate biomarker testing and surge in research & development activities.
North America region is anticipated for the highest revenue share during the forecast period owing to the existence of well-established Contract Research Organizations (CROs) with a specialization in providing biomarker services, increasing demand for outsourcing biomarker services due to the rising research & development investments made by companies in the life sciences & pharmaceutical sectors, growing number of pharmaceutical companies are showing a preference for outsourcing their manufacturing services to Contract Research Organizations (CROs), and rising collaborations within market players. For instance, in March 2023, Fujirebio Holdings Inc., a contract development and manufacturing organization, has joined forces with AriBio Co., Ltd. to collaborate on the development of specific biomarkers for Alzheimer's disease and other neurodegenerative disorders. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in the number of clinical trial activities driven by supportive regulatory reforms & cost-effective clinical research options, the existence of facilities approved by regulatory bodies such as the U.S. FDA & European Medicines Agency in emerging regional economies is expected to attract foreign investments, and increasing partnerships & collaborations within market players. For instance, in July 2023, Eisai Co., Ltd. and Biogen Inc. have disclosed that a comprehensive analysis of the Phase 3 Clarity AD study has revealed that Lecanemab-Irmb (LEQEMBI) treatment led to reductions in amyloid-beta (Aβ) pathology and changes in downstream biomarkers.
Segmentation: Biomarker Clinical Phase Outsourcing Services Market Report 2023 - 2034
Biomarker Clinical Phase Outsourcing Services Market Analysis & Forecast by Biomarker Type 2023 - 2034 (Revenue USD Bn)
- Safety Biomarkers
- Predictive Biomarkers
- Surrogate Endpoints
- Prognostic Biomarkers
Biomarker Clinical Phase Outsourcing Services Market Analysis & Forecast by Therapeutic Area 2023 - 2034 (Revenue USD Bn)
- Cardiology
- Neurology
- Oncology
- Autoimmune Diseases
- Others
Biomarker Clinical Phase Outsourcing Services Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Biotechnology Companies
- Pharmaceutical Companies
- Others
Biomarker Clinical Phase Outsourcing Services Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Biomarker Clinical Phase Outsourcing Services Market: Biomarker Type Estimates & Trend Analysis
8. Biomarker Clinical Phase Outsourcing Services Market: Therapeutic Area Estimates & Trend Analysis
9. Biomarker Clinical Phase Outsourcing Services Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Biomarker Clinical Phase Outsourcing Services Market
12. Europe Global Biomarker Clinical Phase Outsourcing Services Market
13. Asia Pacific Global Biomarker Clinical Phase Outsourcing Services Market
14. Latin America Global Biomarker Clinical Phase Outsourcing Services Market
15. MEA Global Biomarker Clinical Phase Outsourcing Services Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- GenScript ProBio
- Parexel International Corporation
- Fujirebio
- WuXi AppTec
- ICON plc
- Charles River Laboratories
- Proteome Sciences
- Laboratory Corporation of America Holdings
- Celerion
- NorthEast BioAnalytical Laboratories LLC.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 7.43 Billion |
| Forecasted Market Value ( USD | $ 59.07 Billion |
| Compound Annual Growth Rate | 20.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
